Last reviewed · How we verify
MCT/LCT/omega-3 (5:4:1)
This intravenous lipid emulsion provides a balanced mixture of medium-chain triglycerides, long-chain triglycerides, and omega-3 fatty acids to support nutritional requirements in parenteral nutrition.
This is a lipid emulsion combining medium-chain triglycerides (MCT), long-chain triglycerides (LCT), and omega-3 fatty acids to provide balanced nutritional support and reduce metabolic complications in parenteral nutrition. Used for Parenteral nutrition in patients requiring intravenous lipid supplementation, Nutritional support in critically ill or post-operative patients.
At a glance
| Generic name | MCT/LCT/omega-3 (5:4:1) |
|---|---|
| Also known as | LIPOPLUS |
| Sponsor | B. Braun Medical SA |
| Drug class | Lipid emulsion for parenteral nutrition |
| Modality | Small molecule |
| Therapeutic area | Nutrition support / Critical care |
| Phase | FDA-approved |
Mechanism of action
MCT/LCT/omega-3 emulsions are used as lipid components in total parenteral nutrition (TPN) formulations. The medium-chain triglycerides provide rapid energy, long-chain triglycerides supply essential fatty acids and sustained energy, and omega-3 fatty acids (fish oil-derived) provide anti-inflammatory benefits and support immune function. This balanced ratio optimizes energy delivery while reducing lipid-associated complications compared to LCT-only formulations.
Approved indications
- Parenteral nutrition in patients unable to receive adequate enteral nutrition
- Perioperative nutritional support
- Critical illness requiring total parenteral nutrition
Common side effects
- Hypertriglyceridemia
- Lipemia
- Infusion site reactions
- Hepatic steatosis (with prolonged use)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MCT/LCT/omega-3 (5:4:1) CI brief — competitive landscape report
- MCT/LCT/omega-3 (5:4:1) updates RSS · CI watch RSS
- B. Braun Medical SA portfolio CI